Faron Pharmaceuticals Oy, a clinical stage biopharmaceutical company, has announced that its Chief Executive Officer, Dr. Markku Jalkanen, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024, in San Francisco. The presentation will be accessible through the "Investors" section of the Company's website and will be available following the event.
Faron Pharmaceuticals is a global, clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies. The company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments and as a monotherapy in last line solid cancers.
For more information, investors can contact LifeSci Advisors, ICR Consilium, Cairn Financial Advisers LLP, Peel Hunt LLP, or Sisu Partners Oy. This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange.